

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
 (Under 37 CFR 1.97(b) or 1.97(c))

 Docket No.
 RLL-308US

 In Re Application Of: **TREHAN et al.**
10/534909

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/534,909	11/13/2003	TBA	26815	TBA	5762

Title:

PHARMACEUTICAL COMPOSITIONS CONTAINING A BIGUANIDE-GLITAZONE COMBINATION

 Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

Docket No.
RLL-308US

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/534,909	11/13/2003	TBA	26815	TBA	5762

PHARMACEUTICAL COMPOSITIONS CONTAINING A BIGUANIDE-GLITAZONE COMBINATION

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **50-0912** as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

(Date)

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Certificate

Dated: November 16, 2005

CC:

INFORMATION DISCLOSURE CITATION

Docket No.: RLL-308US

Serial No.: 10/534,909

Applicants: M. AN *et al.*

Filed: 5/13/2005

Group:

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	6,011,049	1/4/2000	Whitcomb	514	369	
	A2	6,166,043	12/26/2000	Ikeda <i>et al.</i>	514	342	
	A3	6,172,090	1/9/2001	Ikeda <i>et al.</i>	514	342	
	A4	6,296,874	10/2/2001	Cutie <i>et al.</i>	424	474	
	A5	2001/0034374	10/25/2001	Adjei <i>et al.</i>	514	635	
	A6	2001/0036478	11/1/2001	Adjei <i>et al.</i>	424	481	
	A7	2001/0046515	11/29/2001	Adjei <i>et al.</i>	424	465	
	A8	2003/187074	10/2/2003	Hussain <i>et al.</i>	514	635	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	B1	WO 00/27401	5/18/2000	PCT	A61K	31/64		
	B2	WO 01/82867	11/8/2001	PCT	A61K			
	B3	WO 01/82875	11/8/2001	PCT	A61K			
	B4	WO 01/82904	11/8/2001	PCT	A61K	9/32		
	B5	WO 03/28704	4/10/2003	PCT	A61K	9/16		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.